| Mar 20, 2026 |
BiomX |
—
|
—
|
Ness Ziona, Israel |
Discontinued BX004 trial; high adverse events |
—
|
BioSpace
|
| Mar 20, 2026 |
Gossamer Bio |
77
|
48%
|
San Diego, CA |
Phase 3 failure of seralutinib in PAH |
—
|
BioSpace
|
| Mar 18, 2026 |
Bicycle Therapeutics |
86
|
30%
|
Cambridge, UK |
FDA rejection of zelenectide; shelving lead drug |
—
|
Fierce Biotech
|
| Mar 16, 2026 |
Inovio Pharmaceuticals |
18
|
16%
|
Plymouth Meeting, PA |
Cost optimization before INO-3107 launch |
—
|
BioSpace
|
| Mar 12, 2026 |
Vistagen Therapeutics |
12
|
20%
|
South San Francisco, CA |
PALISADE-3 trial failed for fasedienol |
—
|
BioSpace
|
| Mar 12, 2026 |
Reckitt Benckiser |
62
|
—
|
Parsippany, NJ |
Cost reduction; Mucinex sales decline |
—
|
BioSpace
|
| Mar 11, 2026 |
F5 Therapeutics |
10
|
100%
|
San Diego, CA |
Company closure; unable to secure funding |
—
|
BioSpace
|
| Mar 11, 2026 |
Horizon Therapeutics (Amgen) |
22
|
—
|
Rockville, MD |
Post-acquisition restructuring by Amgen |
—
|
BioSpace
|
| Mar 09, 2026 |
Vertex Pharmaceuticals |
20
|
—
|
Boston, MA |
Functional reorganization |
0
|
BioSpace
|
| Mar 08, 2026 |
Tessera Therapeutics |
90
|
35%
|
Somerville, MA |
Shifting focus to Regeneron gene-editing partnership |
2
|
Fierce Biotech
|
| Mar 06, 2026 |
Alltrna |
19
|
34%
|
Massachusetts |
Restructuring toward clinical development |
—
|
Fierce Biotech
|
| Mar 05, 2026 |
EveryONE Medicines |
—
|
100%
|
Unknown |
Company closure; FDA pathway insufficient |
—
|
BioSpace
|
| Mar 04, 2026 |
Theravance Biopharma |
—
|
50%
|
South San Francisco, CA |
Phase 3 CYPRESS failure; shutting down R&D |
—
|
BioSpace
|
| Mar 03, 2026 |
BioAtla |
—
|
70%
|
San Diego, CA |
Exploring asset sales and licensing |
—
|
Metaintro
|
| Mar 02, 2026 |
Merck (MSD) |
154
|
—
|
Durham, NC |
Gardasil production halt due to demand reduction |
702
|
BioSpace
|
| Mar 02, 2026 |
Disc Medicine |
30
|
20%
|
Cambridge, MA |
FDA rebuff of bitopertin |
7
|
BioSpace
|
| Mar 01, 2026 |
Adare Pharmaceuticals |
137
|
—
|
Philadelphia, PA, USA |
Facility closure |
—
|
PA WARN Act
|
| Feb 26, 2026 |
Viatris |
3,200
|
10%
|
Global (HQ: Canonsburg, PA) |
3-year restructuring overhaul; India plant fire aftermath |
279
|
Fierce Pharma
|
| Feb 23, 2026 |
Catalent |
93
|
—
|
Harmans, MD |
Gene therapy demand shift; Baltimore site reduction |
316
|
Fierce Pharma
|
| Feb 23, 2026 |
Bristol Myers Squibb |
247
|
—
|
Lawrenceville, NJ |
Cost reduction; site consolidation |
756
|
BioSpace
|
| Feb 18, 2026 |
Faraday Pharmaceuticals |
—
|
100%
|
Seattle, WA |
Company closure; FDY-5301 Phase 3 failure |
—
|
BioSpace
|
| Feb 18, 2026 |
Concerto Biosciences |
—
|
—
|
Unknown |
Strategic shift to consumer products |
—
|
BioSpace
|
| Feb 12, 2026 |
Ultragenyx Pharmaceutical |
130
|
10%
|
Novato, CA |
Phase 3 setrusumab failures for brittle bone disease |
—
|
Fierce Biotech
|
| Feb 12, 2026 |
Seres Therapeutics |
31
|
30%
|
Cambridge, MA |
Pipeline refocusing; pausing SER-155 investment |
—
|
Xtalks
|
| Feb 09, 2026 |
Genentech |
141
|
—
|
South San Francisco, CA |
Previously undisclosed staff reduction |
—
|
BioSpace
|
| Feb 06, 2026 |
Charles River Laboratories |
20
|
—
|
Hanover, MD |
Cell therapy site closure |
—
|
BioSpace
|
| Feb 06, 2026 |
Thermo Fisher Scientific |
103
|
—
|
Franklin, MA |
Production plant closure |
—
|
BioSpace
|
| Feb 01, 2026 |
Integra Life Sciences |
65
|
—
|
Princeton, NJ, USA |
Site restructuring |
—
|
NJ WARN Act
|
| Jan 30, 2026 |
IO Biotech |
—
|
—
|
Copenhagen, Denmark |
FDA rejection of Cylembio; exploring merger/sale/dissolution |
—
|
Stock Titan
|
| Jan 29, 2026 |
Gilead Sciences |
34
|
—
|
Oceanside, CA |
Oceanside clinical manufacturing site reduction |
264
|
PharmaLive
|
| Jan 19, 2026 |
Vedanta Biosciences |
46
|
50%
|
Cambridge, MA |
Maintaining focus on VE303 Phase III for C. difficile |
0
|
BioSpace
|
| Jan 15, 2026 |
Bitterroot Bio |
—
|
—
|
California |
Restructuring from clinical to preclinical; abandoned CD47 trial |
—
|
BioSpace
|
| Jan 14, 2026 |
Curia Global |
81
|
—
|
Burlington, MA, USA |
CDMO site reduction |
—
|
MA WARN Act
|
| Jan 14, 2026 |
Takeda |
243
|
—
|
US (47 states) |
Trintellix patent expiration; field force reduction |
1321
|
Fierce Pharma
|
| Jan 13, 2026 |
Sonoma Biotherapeutics |
—
|
—
|
South San Francisco, CA |
Right-sizing; concentrating on RA candidate |
—
|
Xtalks
|
| Jan 13, 2026 |
EMD Serono (Merck KGaA) |
—
|
—
|
Durham, NC |
Streamlining research after SpringWorks acquisition |
—
|
Fierce Biotech
|
| Jan 12, 2026 |
Biolyst Scientific |
76
|
—
|
Hatfield, PA, USA |
Company closure |
—
|
PA WARN Act
|
| Jan 12, 2026 |
Rampart Bioscience |
—
|
100%
|
Unknown |
Company closure; ended DNA-based therapy development |
—
|
BioSpace
|
| Jan 12, 2026 |
Lyra Therapeutics |
28
|
100%
|
Watertown, MA |
Halted LYR-210 development; company wind-down |
—
|
Fierce Biotech
|
| Jan 08, 2026 |
Labcorp |
94
|
—
|
Bedford, MA, USA |
Site reduction |
—
|
MA WARN Act
|
| Jan 08, 2026 |
InflaRx |
—
|
30%
|
Jena, Germany |
Capital efficiency restructuring |
—
|
Fierce Biotech
|
| Jan 06, 2026 |
Med-Pharmex |
130
|
—
|
Los Angeles, CA, USA |
Facility closure |
—
|
CA WARN Act
|
| Jan 02, 2026 |
Nido Biosciences |
—
|
100%
|
Massachusetts |
Pipeline failure; company shutdown |
—
|
Xtalks
|
| Dec 17, 2025 |
Voyager Therapeutics |
30
|
—
|
Massachusetts, USA |
Partnership program discontinuation |
2
|
Xtalks
|
| Dec 17, 2025 |
Intercept Pharmaceuticals |
146
|
—
|
USA |
Drug withdrawal; regulatory setbacks |
—
|
Xtalks
|
| Dec 11, 2025 |
Geron Corporation |
87
|
33%
|
California, USA |
Strategic restructuring |
—
|
Xtalks
|
| Dec 11, 2025 |
Pfizer |
230
|
67%
|
Zurich, Switzerland |
Swiss operations consolidation; $7.7B global savings target |
597
|
Fierce Pharma
|
| Dec 09, 2025 |
bioMérieux |
121
|
—
|
Santa Clara, CA, USA |
Site closure |
—
|
CA WARN Act
|
| Dec 01, 2025 |
GSK |
350
|
—
|
USA / UK |
R&D reorientation; investing in technology for productivity |
663
|
Fierce Biotech
|
| Nov 26, 2025 |
Valneva |
30
|
77%
|
Nantes, France |
Nantes site closure; consolidating R&D in Vienna |
—
|
Fierce Biotech
|
| Nov 25, 2025 |
Novartis |
550
|
—
|
Stein, Switzerland |
Phase-out of tablet/capsule production; manufacturing modernization |
658
|
Xtalks
|
| Nov 14, 2025 |
Sensei Biotherapeutics |
—
|
65%
|
Boston, MA, USA |
Sale evaluation; development wind-down |
—
|
Xtalks
|
| Nov 13, 2025 |
Kite Pharma (Gilead) |
17
|
—
|
California, USA |
Biologics manufacturing pause |
—
|
Xtalks
|
| Nov 10, 2025 |
Charles River Laboratories |
68
|
—
|
Wilmington, MA, USA |
Site reduction |
—
|
MA WARN Act
|
| Nov 05, 2025 |
Illumina |
63
|
—
|
San Diego, CA, USA |
Multi-wave workforce reduction |
—
|
CA WARN Act
|
| Nov 04, 2025 |
Arena BioWorks |
50
|
—
|
USA |
Changing biotech macro conditions |
—
|
Xtalks
|
| Nov 01, 2025 |
Nxera Pharma |
56
|
15%
|
Japan / Cambridge, UK |
Profitability push; prioritizing obesity/metabolic pipeline |
—
|
Fierce Biotech
|
| Nov 01, 2025 |
Evotec |
800
|
17%
|
Hamburg, Germany (+ 13 sites) |
Horizon restructuring; closing 4 facilities; EUR 75M savings by 2027 |
70
|
Fierce Biotech
|
| Oct 29, 2025 |
Genentech |
118
|
—
|
California, USA |
Ongoing restructuring (700+ cumulative over 15 months) |
—
|
Xtalks
|
| Oct 22, 2025 |
Galapagos |
365
|
—
|
Belgium / Netherlands / Switzerland / USA / China |
Cell-therapy unit shutdown; no viable buyer found |
—
|
Fierce Biotech
|
| Oct 01, 2025 |
Takeda |
380
|
—
|
Massachusetts / USA |
Discontinuing cell therapy efforts; neuroscience team reduction |
1318
|
Xtalks
|
| Sep 29, 2025 |
Sutro Biopharma |
54
|
—
|
South San Francisco, CA, USA |
Workforce reduction |
—
|
CA WARN Act
|
| Sep 16, 2025 |
Arsenal Biosciences |
100
|
—
|
South San Francisco, CA, USA |
Workforce reduction |
—
|
CA WARN Act
|
| Sep 10, 2025 |
Revvity |
253
|
—
|
Boston / Lawrence, MA, USA |
Multi-wave restructuring (formerly PerkinElmer life sciences) |
—
|
MA WARN Act
|
| Sep 10, 2025 |
Novo Nordisk |
9,000
|
11%
|
Global (~5,000 in Denmark) |
Cost-efficiency initiative under new CEO; competition from Eli Lilly |
358
|
Fierce Pharma
|
| Aug 18, 2025 |
CSL Behring |
3,000
|
15%
|
Global (HQ: Australia) |
R&D streamlining; vaccine unit spin-out; closing 22 US plasma centers |
—
|
PharmExec
|
| Aug 08, 2025 |
TriLink Biotechnologies (Maravai) |
90
|
—
|
San Diego, CA, USA |
Multi-site layoffs |
—
|
CA WARN Act
|
| Aug 08, 2025 |
Iovance Biotherapeutics |
230
|
19%
|
USA |
Weaker-than-expected TIL therapy revenue |
20
|
Xtalks
|
| Aug 05, 2025 |
BioNTech |
90
|
—
|
Maryland / Massachusetts, USA |
Strategic alignment; cell therapy manufacturing review |
263
|
Fierce Biotech
|
| Aug 01, 2025 |
Bayer |
12,000
|
12%
|
Global (HQ: Leverkusen, Germany) |
Dynamic Shared Ownership restructuring; $2.3B annual savings target (cumulative 2024–2026) |
304
|
PharmExec
|
| Jul 31, 2025 |
Poseida Therapeutics |
52
|
—
|
San Diego, CA, USA |
Workforce reduction |
—
|
CA WARN Act
|
| Jul 31, 2025 |
Moderna |
800
|
10%
|
Global (18 countries) |
Slowing COVID vaccine sales; $1.5B annual savings target |
159
|
Fierce Pharma
|
| Jul 31, 2025 |
Merck |
6,000
|
8%
|
Global |
$3 billion annual savings target by 2027; restructuring |
680
|
PharmExec
|
| Jul 16, 2025 |
Genentech |
87
|
—
|
South San Francisco, CA, USA |
Ongoing restructuring |
—
|
CA WARN Act
|
| Jul 16, 2025 |
Sarepta Therapeutics |
500
|
36%
|
USA |
Patient deaths linked to gene therapy; pivot to siRNA; $400M savings |
—
|
Fierce Biotech
|
| Jul 11, 2025 |
Century Therapeutics |
72
|
—
|
Philadelphia, PA, USA |
Workforce reduction |
—
|
PA WARN Act
|
| Jul 09, 2025 |
Pacira BioSciences |
71
|
—
|
San Diego, CA, USA |
Manufacturing layoff |
—
|
CA WARN Act
|
| Jul 08, 2025 |
Azurity Pharmaceuticals |
75
|
—
|
Wilmington, MA, USA |
Site reduction |
—
|
MA WARN Act
|
| Jul 01, 2025 |
Spark Therapeutics |
298
|
—
|
Philadelphia, PA, USA |
Phased layoffs across three Philadelphia sites (Roche subsidiary) |
—
|
PA WARN Act
|
| Jul 01, 2025 |
GSK |
150
|
—
|
Cambridge, MA, USA |
Manufacturing-to-R&D site conversion |
663
|
Fierce Biotech
|
| Jun 30, 2025 |
Bristol Myers Squibb |
68
|
—
|
Lawrenceville, NJ, USA |
Portfolio alignment; cost reduction |
750
|
Xtalks
|
| Jun 30, 2025 |
Sage Therapeutics |
338
|
100%
|
Cambridge, MA, USA |
Acquisition by Supernus Pharmaceuticals; wind-down |
—
|
BioSpace
|
| Jun 25, 2025 |
BlueRock Therapeutics |
50
|
—
|
Cambridge, MA, USA |
Research lab closure; operations streamlining |
15
|
Xtalks
|
| Jun 10, 2025 |
Molecular Partners |
40
|
24%
|
Zurich-Schlieren, Switzerland / Concord, MA, USA |
Cash runway extension; reducing research functions |
—
|
Stock Titan
|
| Jun 01, 2025 |
Kyowa Kirin |
52
|
—
|
Princeton, NJ, USA |
North American operations restructuring |
34
|
BioSpace
|
| May 23, 2025 |
Eikon Therapeutics |
55
|
15%
|
USA |
Reduced government funding; market headwinds |
29
|
Xtalks
|
| May 05, 2025 |
Mammoth Biosciences |
24
|
—
|
USA |
Strategic realignment |
—
|
Xtalks
|
| May 05, 2025 |
Biomea Fusion |
—
|
35%
|
USA |
Cash conservation; program refocus |
—
|
Xtalks
|
| May 05, 2025 |
Bristol Myers Squibb |
516
|
—
|
Lawrenceville, NJ, USA |
$2 billion cost-cutting initiative |
750
|
Xtalks
|
| May 01, 2025 |
Teva Pharmaceuticals |
2,893
|
8%
|
Global (HQ: Israel) |
Streamlining operations; accelerating innovative growth |
—
|
BioSpace
|
| Apr 30, 2025 |
Tempest Therapeutics |
21
|
80%
|
USA |
Cash runway extension |
—
|
Xtalks
|
| Apr 30, 2025 |
Pliant Therapeutics |
75
|
45%
|
USA |
Clinical trial suspension; safety concerns |
—
|
Xtalks
|
| Apr 30, 2025 |
Arvinas |
131
|
33%
|
Connecticut, USA |
Capital market challenges |
—
|
Xtalks
|
| Apr 04, 2025 |
Relay Therapeutics |
70
|
—
|
Massachusetts, USA |
Third restructuring in nine months |
8
|
Xtalks
|
| Mar 18, 2025 |
Novartis |
34
|
—
|
San Diego, CA, USA |
Gene therapy production facility closure |
658
|
BioSpace
|
| Mar 18, 2025 |
Merck |
163
|
—
|
Pennsylvania, USA |
Manufacturing facility closure |
680
|
Xtalks
|
| Mar 17, 2025 |
Novartis |
34
|
—
|
San Diego, CA, USA |
Gene therapy production facility closure |
658
|
BioSpace
|
| Mar 17, 2025 |
Novartis |
427
|
—
|
East Hanover, NJ, USA |
Strategic realignment; headquarters restructuring |
658
|
BioSpace
|
| Mar 05, 2025 |
Bristol Myers Squibb |
223
|
—
|
Lawrenceville, NJ, USA |
Restructuring; $3.5B savings target |
750
|
Xtalks
|
| Mar 03, 2025 |
Atara Biotherapeutics |
—
|
50%
|
USA |
CAR-T program suspension; FDA clinical hold |
—
|
Xtalks
|
| Mar 01, 2025 |
Astellas Gene Therapies |
100
|
—
|
South San Francisco, CA, USA |
Biomanufacturing facility closure; consolidation to Sanford, NC |
—
|
BioSpace
|
| Mar 01, 2025 |
Novartis / MorphoSys |
330
|
—
|
Germany / Boston, USA |
Closing sites acquired through $2.9B MorphoSys purchase |
—
|
Xtalks
|
| Mar 01, 2025 |
BioNTech |
1,150
|
—
|
Marburg, Germany |
Financial downturn (EUR 700M loss in 2024); manufacturing restructuring |
263
|
The Munich Eye
|
| Feb 26, 2025 |
Bristol Myers Squibb |
67
|
—
|
New Jersey, USA |
Patent cliff preparation; operational efficiency |
750
|
Xtalks
|
| Feb 14, 2025 |
Bio-Rad Laboratories |
350
|
5%
|
California, USA |
Financial losses; cost structure management |
—
|
Xtalks
|
| Feb 13, 2025 |
Kojin Therapeutics |
25
|
100%
|
Boston, MA, USA |
Operations closure; funding inadequacy |
—
|
Xtalks
|
| Feb 13, 2025 |
Encoded Therapeutics |
60
|
29%
|
USA |
Cash runway extension |
—
|
Xtalks
|
| Feb 06, 2025 |
X4 Pharmaceuticals |
43
|
30%
|
Boston, MA, USA |
Preclinical program pause; cost savings |
—
|
Xtalks
|
| Feb 01, 2025 |
Eisai |
121
|
7%
|
USA |
US operations restructuring; commercial/medical/corporate cuts |
59
|
BioSpace
|
| Jan 31, 2025 |
Thermo Fisher Scientific |
300
|
—
|
Massachusetts, USA |
Strategic adjustments to customer timelines |
—
|
Xtalks
|
| Jan 27, 2025 |
Allakos |
180
|
75%
|
Bay Area, CA, USA |
Failed Phase I trial results; exploring strategic alternatives |
—
|
Xtalks
|
| Jan 22, 2025 |
Biogen |
—
|
—
|
USA (multiple) |
Research unit restructuring; shift to external opportunities |
268
|
Xtalks
|
| Jan 15, 2025 |
Galapagos |
300
|
40%
|
Belgium / France |
Split into two entities; site closures in France and Belgium |
—
|
BioSpace
|